Theratechnologies Announces New Findings for its Lead Investigational Compound TH1902 for the Treatment of Several Additional Cancers

NEXT STORY
Canadian Society of Nephrology selects NexTech AR to Transform its 2021 Annual General Meeting into a Virtual Event
PREV STORY
CENTOGENE and Alnylam Pharmaceuticals Launch a New Clinical Program Aimed at Revolutionizing the Diagnosis of Hereditary Transthyretin-Related Amyloidosis (“ATTRv”)
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Spring Bank Pharmaceuticals Provides Corporate Update and Reports First Quarter 2017 Financial and Operational Results

HOPKINTON, Mass., April 28, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq:SBPH), a ...

author_avatar
NASDAQ Market News

Helsinn Group and Glenmark Pharmaceuticals enter into an exclusive licensing agreement for launch of AKYNZEO® in India and Nepal

author_avatar
NASDAQ Market News

NexImmune Appoints Sol Barer as Chairman of the Board of Directors

author_avatar
NASDAQ Market News